Paul-Emmanuel Goethals founded CSIntell in 2012 followed by MEDraysintell in 2013. He has 28 years of experience in consulting, business development-intelligence and investor relations with a unique understanding of the medical and healthcare markets, especially in Radiotherapy, Radiopharmacy. Throughout these years he made numerous reports on complex markets as well as outstanding company profiles at the full satisfaction of his successive clients.
Paul-Emmanuel holds an MBA from the University of Dallas and is a member of SCIP (Strategic and Competitive Intelligence Professionals, Virginia, USA) and of MIFB (Market Intelligence Forum Belgium).
Prior founding MEDraysintell and CSIntell, Paul-Emmanuel was Vice President Business Development & Capital Markets and Special Counsel to the CEO at Eckert & Ziegler Group, a European group listed in Frankfurt and Brussels, active in cancer therapy, radiometry, nuclear-medical imaging (2009-2012); Director Corporate Business Development & Investor Relations at IBA, a Belgian company listed in Brussels, active in Proton Therapy, Radiopharmacy, Dosimetry and Industrial Sterilization (1998-2009); Project Manager at Strategic Analysis Inc., a US management consulting firm active in Chemical and Pharmaceutical Business Intelligence (1994 - 1998); Finance Director & Board member at Evening Group SA, a Belgian company active in business events (1992-1993) and Marketing Specialist & Product Management at Chemviron Carbon, the European branch of a US chemical group (1989-1992).
Dr. Richard Zimmermann founded Chrysalium Consulting in 2012 and MEDraysintell in 2013. He is a chemistry engineer, with a PhD degree in organic chemistry obtained in 1984 from the University of Strasbourg, France followed by a post-doctoral at Georgetown University, Washington, DC. He has over 30 years of experience in research laboratories of conventional pharmaceutical companies (Beecham, Solvay Pharmaceuticals) in France, Germany and the Netherlands, further as head of the Research and Development team at CIS bio International (acquired by IBA in 2006), then he became in charge of the radiopharmaceutical business development at IBA, to create the nuclear medicine product pipeline of the company.
With Chrysalium Consulting, Richard Zimmermann helps companies in the field of medical applications using radiations, mainly in nuclear medicine (radiopharmaceuticals) with a main focus on business development (evaluation, competition analysis, strategic development, pipeline management) and translational processes (industrialization processes, regulatory constraints and clinical development). He is also founder and president of the Oncidium foundation, aiming at promoting and developing radiotherapeutics www.oncidium-life.org.